Camostat for COVID-19
Camostat has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs, Biomaterials, doi:10.1016/j.biomaterials.2022.121509 ,
A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory, Structural Chemistry, doi:10.1007/s11224-022-02048-1 ,
Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736 ,
Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870 ,
Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.